Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHYF) EBT (2019 - 2025)

Historic EBT for Innate Pharma (IPHYF) over the last 7 years, with Q2 2025 value amounting to -$25.6 million.

  • Innate Pharma's EBT rose 193.0% to -$25.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$106.5 million, marking a year-over-year decrease of 1729.45%. This contributed to the annual value of -$52.9 million for FY2024, which is 54905.28% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's EBT is -$25.6 million, which was up 193.0% from -$48.6 million recorded in Q4 2024.
  • Innate Pharma's 5-year EBT high stood at $7.5 million for Q2 2021, and its period low was -$59.1 million during Q4 2022.
  • Moreover, its 5-year median value for EBT was -$25.9 million (2024), whereas its average is -$25.6 million.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 27442.65% in 2021, then plummeted by 432199.99% in 2024.
  • Quarter analysis of 5 years shows Innate Pharma's EBT stood at -$47.5 million in 2021, then fell by 24.63% to -$59.1 million in 2022, then soared by 89.57% to -$6.2 million in 2023, then tumbled by 687.89% to -$48.6 million in 2024, then soared by 47.32% to -$25.6 million in 2025.
  • Its last three reported values are -$25.6 million in Q2 2025, -$48.6 million for Q4 2024, and -$26.1 million during Q2 2024.